Latest Presentations Scientific Presentations Sangamo Corporate Presentation May 05, 2022 Sangamo Corporate Presentation 2.6 MB Preliminary Results of the STAAR Study, a Phase I/II Study of Isaralgagene Civaparvovec (ST 920) Gene Therapy in Adults With Fabry Disease Feb 08, 2022 Preliminary Results of the STAAR Study, a Phase I/II Study of Isaralgagene Civaparvovec (ST 920) Gene Therapy in Adults With Fabry Disease 1 MB Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD) Dec 12, 2021 Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD) 775.7 KB Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF 07055480/SB 525) Gene Therapy in Adults With Severe Hemophilia A Dec 12, 2021 Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF 07055480/SB 525) Gene Therapy in Adults With Severe Hemophilia A 526.5 KB A Compact Zinc Finger Architecture for Highly Efficient Base Editing in Human Cells May 17, 2022 A Compact Zinc Finger Architecture for Highly Efficient Base Editing in Human Cells 17 MB Upcoming Events Guggenheim I&I Spotlight Series – Treg-based Therapies Jul 12, 2022 at 2:45 PM EDT Add to Outlook Add to Google Calendar Listen to Webcast Past Events Year None2022202120202019 H.C. Wainwright BIOCONNECT Virtual Conference Jan 10, 2022 at 7:00 AM EST Listen to Webcast Pagination Previous page ‹ Previous Page 1 Page 2 Current page 3 Displaying 19 - 19 of 19
Preliminary Results of the STAAR Study, a Phase I/II Study of Isaralgagene Civaparvovec (ST 920) Gene Therapy in Adults With Fabry Disease 1 MB
Preliminary Safety and Efficacy Results from PRECIZN-1: An Ongoing Phase 1/2 Study on Zinc Finger Nuclease-Modified Autologous CD34+ HSPCs for Sickle Cell Disease (SCD) 775.7 KB
Updated Results of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (PF 07055480/SB 525) Gene Therapy in Adults With Severe Hemophilia A 526.5 KB
